※The timeline may change depends on each project.
In need of codon optimization and UTR?
Tailored mRNA design
at your fingertips
In need of clinical or commercial mRNA/LNP?
Brand new cGMP facility dedicated to manufacturing of mRNA/LNP
In need of rapid development?
Achieve success in just 3 months - the fastest route to your development journey
In need of simplification?
One stop solution to simplify outsourcing
In need of large production capacity?
Up to 100g mRNA batch
Your product, our passion and expertise
ARCALIS’ Minamisoma Facility
ARCALIS has built a cGMP mRNA drug substance manufacturing facility in Minamisoma City in July 2023, and the world’s first approved product applying self-amplifying mRNA technology vaccine is planning to commercialize from 2024.The Minamisoma campus will also include a separate drug product manufacturing facility. Once completed in 2026, ARCALIS can offer one-stop manufacturing and release testing of mRNA vaccines and therhapeutics.
News & Events
Feb 22, 2024
Dec 19, 2023